Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Blinatumomab in Philadelphia Chromosome-Negative ALL

Rituximab, Obinutuzumab, and Ofatumumab in CLL

Immunotherapy-Related Adverse Events

Responses With Immunotherapy Versus Chemotherapy

Immunotherapy in Hematologic Malignancies

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma

The European Commission has approved nivolumab as a treatment for patients with advanced melanoma in the first- and later-line setting regardless of BRAF mutation status, making it the first PD-1 inhibitor to gain approval in Europe. 


First PD-1 Inhibitor Approved in Europe

For clinicians, a central message from 2015 ASCO is that a framework for managing immune-related adverse events in patients who receive these immune checkpoint agents is taking shape.

Practical Advice for Immunotherapy Era Emerges From ASCO

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

Nivolumab Elicits Durable Responses in Lymphoma

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer. 

Researchers Explore Immunotherapy With XBP1 Inhibition in Ovarian Cancer

History and Evolution of Immuno-oncology

Clinical Trial Design for Immunotherapy

Phase I Immunotherapy Trials

Biomarkers and Immunotherapy

Identifying and Managing Toxicities of Immunotherapy

Patient Selection for Immunotherapies

Emerging Agents and Approaches in Immunotherapy

Advances in Immuno-Oncology

ImmunoScore: Predictive and Prognostic?

Society for Immunotherapy in Cancer

Immuno-Oncology

Immuno-Oncology | Specialty